Non-Small Cell Lung Cancer (NSCLC)

Treatment with adagrasib in the phase 3 KRYSTAL-12 trial raised no new safety signals among patients with KRAS G12C–mutated non–small cell lung cancer.

Data from the phase 3 KEYNOTE-671 trial support the European Commission’s approval of pembrolizumab plus chemotherapy for those with resectable non–small cell lung cancer.

Intracranial disease control with Ivonescimab plus chemotherapy appears encouraging in patients with non–small cell lung cancer and brain metastases.

A 50% objective response rate was observed when becotarug plus osimertinnib was combined to treat patients with EGFR exon 12 non–small cell lung cancer.

Treatment with osimertinib plus chemotherapy also shows a consistent survival benefit across prespecified NSCLC subgroups in the phase 3 FLAURA2 trial.

The phase 3 KEYLYNK-006 trial did not meet the primary end points of progression-free and overall survival in patients with metastatic nonsquamous non–small cell lung cancer.

The regulatory agency set an action date of December 28, 2024 for ensartinib as a treatment for those with ALK-positive non–small cell lung cancer.

A cohort study for patients with non–small cell lung cancer found an overall survival benefit when targeted therapies were utilized.

Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.

Developers also announced that they completed enrollment of patients with non–small cell lung cancer in the phase 2 THIO-101 trial.

Data from the TROPION-Lung01 and TROPION-Breast01 trials support the EU marketing authorization applications for datopotamab deruxtecan in non–small cell lung cancer and breast cancer, respectively.

The regulatory agency has cleared developers to continue patient enrollment in the phase 2 IOV-LUN-202 trial evaluating LN-145 in non–small cell lung cancer.

Data from the phase 3 PAPILLON trial support the FDA approval of amivantamab plus chemotherapy for patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

The nivolumab with chemotherapy regimen missed the primary end point on the phase 3 trial of patients with EGFR-mutated non–small cell lung cancer.

Data from the phase 1 portion of the ARROS-1 trial support the breakthrough therapy designation for NVL-520 as a treatment for those with ROS1-positive non–small cell lung cancer.

Findings from 3 phase 3 trials support the marketing authorization application for tislelizumab as a treatment for patients with non–small cell lung cancer in the European Union.

Preliminary findings from a phase 1 trial support the breakthrough therapy designation for BAY 2927088 as a treatment for those with unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.

The European Medicine Agency’s Committee for Medicinal Products for Human Use’s recommendation of approving pembrolizumab plus chemotherapy in resectable non–small cell lung cancer is based on results from the KEYNOTE-671 trial.

Results from the phase 3 LAURA trial found a statistically significant PFS benefit and a positive trend in OS with osimertinib following chemoradiotherapy in patients with stage III EGFR-mutated non–small cell lung cancer.

Findings from the phase 3 TROPION-Lung01 trial support the biologics license application for datopotamab deruxtecan as a treatment for those with advanced nonsquamous non–small cell lung cancer.

Findings from the phase 2 UNICORN trial support osimertinib as a potential treatment option for patients with metastatic non–small cell lung cancer harboring uncommon EGFR mutations.

Secondary primary lung cancer rates and cumulative incidence rates were similar in multiple subgroups of patients with stage T1aN0 non–small cell lung cancer.

Data from the phase 3 FLAURA 2 trial support the FDA approval of osimertinib plus chemotherapy for treating patients with EGFR-mutated non–small cell lung cancer.

Data from the phase 3 RATIONALE-315 study support the use of perioperative tislelizumab plus neoadjuvant chemotherapy in resectable stage II to IIIA non–small cell lung cancer.

Narjust Florez, MD, and Sandip P. Patel, MD, cohosted a X chat centering on treatment options for KRAS G12C non–small cell lung cancer.

Results from the phase 2 VISION trial have allowed for tepotinib to receive full approval by the FDA in non–small cell lung cancer harboring MET exon 14 skipping alterations.

The FDA set a Prescription Drug User Fee Act date of June 15, 2024 for repotrectinib as a treatment for those with advanced or metastatic solid tumors harboring an NTRK gene fusion.

The CROWN and ADURA trials were discussed and defended as part of a non–small cell lung cancer Face Off.

Data from the phase 3 MARIPOSA study support the Type II application for amivantamab plus lazertinib as a treatment for those with EGFR-mutated non–small cell lung cancer.